Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Emerging Treatments and Technologies

The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid

  1. The SYDNEY Trial Authors, for the SYDNEY Trial Study Group:,
  2. Alexander S. Ametov, MD1,
  3. Alexei Barinov, MD2,
  4. Peter J. Dyck, MD3,
  5. Robert Hermann, MD4,
  6. Natalia Kozlova, MD5,
  7. William J. Litchy, MD6,
  8. Phillip A. Low, MD3,
  9. Detlef Nehrdich, DIPL STAT4,
  10. Maria Novosadova, MD5,
  11. Peter C. O’Brien, PHD3,
  12. Miroslav Reljanovic, MD6,
  13. Rustem Samigullin, MD4,
  14. Klemens Schuette, BSC3,
  15. Igor Strokov, MD1,
  16. Hans J. Tritschler, PHD4,
  17. Klaus Wessel, PHD4,
  18. Nikolai Yakhno, MD2 and
  19. Dan Ziegler, MD7
  1. 1Russian Medical Academy for Advanced Studies, Moscow, Russia
  2. 2Neurology Clinic, Moscow Medical Academy, Russia
  3. 3Mayo Clinic, Rochester, Minnesota
  4. 4Viatris GmbH, Frankfurt, Germany
  5. 5Health Partners Medical Group, Minneapolis, Minnesota
  6. 6Ergomed, Zagreb, Croatia
  7. 7German Diabetes Research Institute, University of Düsseldorf, Germany
    Diabetes Care 2003 Mar; 26(3): 770-776. https://doi.org/10.2337/diacare.26.3.770
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    This article has a correction. Please see:

    • Erratum - July 01, 2003

    The SYDNEY Trial

    Abstract

    OBJECTIVE— Because α-lipoic acid (ALA), a potent antioxidant, prevents or improves nerve conduction attributes, endoneurial blood flow, and nerve (Na(+) K(+) ATPase activity in experimental diabetes and in humans and may improve positive neuropathic sensory symptoms, in this report we further assess the safety and efficacy of ALA on the Total Symptom Score (TSS), a measure of positive neuropathic sensory symptoms.

    RESEARCH DESIGN AND METHODS— Metabolically stable diabetic patients with symptomatic (stage 2) diabetic sensorimotor polyneuropathy (DSPN) were randomized to a parallel, double-blind study of ALA (600 mg) (n = 60) or placebo (n = 60) infused daily intravenously for 5 days/week for 14 treatments. The primary end point was change of the sum score of daily assessments of severity and duration of TSS. Secondary end points were sum scores of neuropathy signs (NIS), symptoms (NSC), attributes of nerve conduction, quantitative sensation tests (QSTs), and an autonomic test.

    RESULTS— At randomization, the groups were not significantly different by the criteria of metabolic control or neuropathic end points. After 14 treatments, the TSS of the ALA group had improved from baseline by an average of 5.7 points and the placebo group by an average of 1.8 points (P < 0.001). Statistically significant improvement from baseline of the ALA, as compared with the placebo group, was also found for each item of the TSS (lancinating and burning pain, asleep numbness and prickling), NIS, one attribute of nerve conduction, and global assessment of efficacy.

    CONCLUSIONS— Intravenous racemic ALA, a potent antioxidant, rapidly and to a significant and meaningful degree, improved such positive neuropathic sensory symptoms as pain and several other neuropathic end points. This improvement of symptoms was attributed to improved nerve pathophysiology, not to increased nerve fiber degeneration. Because of its safety profile and its effect on positive neuropathic sensory symptoms and other neuropathic end points, this drug appears to be a useful ancillary treatment for the symptoms of diabetic polyneuropathy.

    • ALA, α-lipoic acid
    • DSPN, diabetic sensorimotor polyneuropathy
    • HP-DB, heart pulse deep breathing
    • ITT, intent-to-treat
    • NIS, neuropathy impairment score
    • NIS(LL), NIS of lower limbs
    • NSC, neuropathy symptoms and change
    • NSC(LL), neuropathy symptoms and change of lower limbs
    • PP, per protocol
    • QST, quantitative sensation test
    • TSS, Total Symptom Score

    Footnotes

    • This report was prepared by P.J.D.

      Address correspondence and reprint requests to Peter J. Dyck, MD, Mayo Clinic, 200 First St. SW, Rochester, MN 55905. E-mail: dyck.peter{at}mayo.edu.

      Received for publication 1 August 2002 and accepted in revised form 10 December 2002.

      P.J.D., W.J.L., P.A.L., and D.Z. have received honoraria from Vitaris GmbH and/or have served on an advisory panel for Vitaris GmbH, the manufacturer of α-lipoic acid.

      A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • DIABETES CARE
    View Full Text
    PreviousNext
    Back to top
    Diabetes Care: 26 (3)

    In this Issue

    March 2003, 26(3)
    • Table of Contents
    • About the Cover
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes Care.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid
    (Your Name) has forwarded a page to you from Diabetes Care
    (Your Name) thought you would like to see this page from the Diabetes Care web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid
    Alexander S. Ametov, Alexei Barinov, Peter J. Dyck, Robert Hermann, Natalia Kozlova, William J. Litchy, Phillip A. Low, Detlef Nehrdich, Maria Novosadova, Peter C. O’Brien, Miroslav Reljanovic, Rustem Samigullin, Klemens Schuette, Igor Strokov, Hans J. Tritschler, Klaus Wessel, Nikolai Yakhno, Dan Ziegler
    Diabetes Care Mar 2003, 26 (3) 770-776; DOI: 10.2337/diacare.26.3.770

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid
    Alexander S. Ametov, Alexei Barinov, Peter J. Dyck, Robert Hermann, Natalia Kozlova, William J. Litchy, Phillip A. Low, Detlef Nehrdich, Maria Novosadova, Peter C. O’Brien, Miroslav Reljanovic, Rustem Samigullin, Klemens Schuette, Igor Strokov, Hans J. Tritschler, Klaus Wessel, Nikolai Yakhno, Dan Ziegler
    Diabetes Care Mar 2003, 26 (3) 770-776; DOI: 10.2337/diacare.26.3.770
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Study design and demographic characteristics of patients
      • Assessment of neuropathic end points
      • Analysis plan
      • RESULTS
      • CONCLUSIONS
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide
    • Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
    • Diabetes Antibody Standardization Program
    Show more Emerging Treatments and Technologies

    Similar Articles

    Navigate

    • Current Issue
    • Standards of Care Guidelines
    • Online Ahead of Print
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.